In the phase 3 REZILIENT 3 trial, zipalertinib plus platinum-pemetrexed chemotherapy extended median progression-free survival for advanced NSCLC patients with EGFR exon 20 insertion mutations. The study reported an increase from 8.5 months with chemotherapy alone to 14.5 months with the combination in the first-line setting. The results support a growing category of targeted therapies designed to address EGFR exon 20 alterations, where responses to earlier EGFR approaches have often been limited. By positioning zipalertinib in combination with standard chemotherapy, the trial frames a practical sequencing option for front-line treatment. For the development pipeline, the key implication is competitive pressure in the EGFR exon 20 market—potentially accelerating further biomarker refinement, combination studies, and payer discussions around efficacy and durability.